Rhelion says Filament Health wins new US patent for controlled extraction of psychoactive alkaloids

• Rhelion Life Sciences reported a new U.S. patent issued to its Filament Health unit for “Dephosphorylation-Controlled Extraction of Phosphorylatable Psychoactive Alkaloids.”
• The patent expands the intellectual property backing PEX010, its GMP botanical psilocybin drug candidate used in more than 80 studies.
• Rhelion said Filament’s portfolio now totals 77 issued patents across 13 patent families following the grant.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rhelion Life Sciences Corp. published the original content used to generate this news brief via Newsfile (Ref. ID: 202608270824NEWSFILECNPR____20260827_311795_1) on August 27, 2026, and is solely responsible for the information contained therein.